1049809-94-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
N-(4-chlorobenzyl)(4-ethynylphenyl)methanamine is employed as a potential candidate for developing new medications, particularly in the field of central nervous system disorders. Its specific biological and pharmacological properties make it a valuable tool in the investigation of potential treatments for various medical conditions.
Used in the Investigation of Potential Treatments for Medical Conditions:
This chemical compound is used as a research tool to explore its potential in treating various medical conditions. Its unique structure and properties allow scientists to study its interactions with biological systems and evaluate its efficacy in addressing specific health issues.
Used in the Development of Potential Therapeutic Agents:
N-(4-chlorobenzyl)(4-ethynylphenyl)methanamine is utilized in the development of potential therapeutic agents due to its versatile chemical structure. Its ability to be modified and combined with other compounds makes it a valuable asset in the creation of new and effective medications for a range of diseases and disorders.

Upstream product

• 63697-96-1 4-Ethynylbenzaldehyde 
• 104-86-9 4-chlorobenzylamine 
• 77123-57-0 4-[(trimethylsilyl)ethynyl]bezaldehyde 

Downstream Products

• 1049808-54-9 (4-Chloro-benzyl)-(4-{2-chloro-5-[5-methanesulfonyl-1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]-phenylethynyl}-benzyl)-amine 
• 1181359-24-9 2-{3-(4-chloro-3-{4-[(4-chloro-benzylamino)-methyl]-phenylethynyl}-phenyl)-1-[3-(3-methyl-morpholin-4-yl)-propyl]-1,4,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-5-yl}-2-oxo-acetamide L-tartrate 
• 1422264-36-5 C₂₁H₂₂ClNO₂ 
• 1049809-77-9 C₁₈H₁₃ClF₃NO 
• 1422264-37-6 C₃₈H₃₉Cl₂N₅O₅ 
• 1049810-13-0 (4-[5-[5-Carbamoyl-(3-hydroxy-propyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[4,3-c]pyridin-3-yl]-2-chloro-phenylethynyl]-benzyl)-(4-chloro-benzyl)-carbamic acid tert-butyl ester 
• 1049817-58-4 3-(4-Chloro-3-{[4-({[(4-chlorophenyl)methyl]amino}methyl)phenyl]ethynyl}phenyl)-N-methyl-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide 
• 1049809-78-0 N-(4-chloro-benzyl)-N-(4-{2-chloro-5-[1-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenylethynyl}-benzyl)-2,2,2-trifluoro-acetamide 
• 1049817-50-6 3-(4-chloro-3-((4-((((4-chlorophenyl)methyl)amino)methyl)phenyl)ethynyl)phenyl)-1-(3-morpholin-4-ylpropyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide 
• 1049813-33-3 3-(4-chloro-3-((4-((((4-chlorophenyl)methyl)amino)methyl)phenyl)ethynyl)phenyl)-1-(3-((3S)-3-methylmorpholin-4-yl)propyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide 
• 1049810-02-7 1-[4-({2-Chloro-5-[1-(3-morpholin-4-ylpropyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]phenyl}ethynyl)phenyl]-N-[(4-chlorophenyl)methyl]methanamine 
• 1049817-65-3 C₃₆H₃₈Cl₂N₆OS 

Relevant academic research and scientific papers

Pyrazole-based arylalkyne Cathepsin S inhibitors. Part III: Modification of P4 region

Novel classes of tetrahydropyrido-pyrazole thioether amines and arylalkynes that display potency against human Cathepsin S have been previously reported. Here, key pharmacophoric elements of these two classes are merged, and SAR investigations of the P4 region are described, in conjunction with re-optimization of the P5 and P1/P1′/P3 regions. Identification of meta-substituted arylalkynes with good potency and improved solubility is described.

Practical synthesis of a cathepsin S Inhibitor: Route identification, purification strategies, and serendipitous discovery of a crystalline salt form

Chemical Equation Presented A redox economical strategy resulted in a concise, modular synthesis of compound 1, a potent Cathepsin S inhibitor. Starting from three building blocks, crude drug substance was prepared, in a two-step sequence in high yield. Efficient purification of the crude drug substance was accomplished via the formation of an unusual monoethyl oxalate salt.

PROCESSES FOR THE PREPARATION OF CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

Method of making carbon-linked tetrahydro-pyrazolo-pyridine compounds of the following Formula (I) and pharmaceutically acceptable salts thereof: comprising reacting a compound of formula (IX): with a compound of formula (X): to form a compound of Formula

Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: Optimization of cellular potency

Basic lipophilic substituents dramatically improved the cellular potency of a previously disclosed series of pyrazole-based arylalkyne cathepsin S inhibitors. The incorporation of substituted benzylamines in the para position of the arylalkyne maintained

CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S

Carbon-linked tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.